Regencell Bioscience Holdings Limited (RGC) |
|
21.6701 -0.35 (-1.59%)
|
05-30 10:20 |
|
Open: |
21.8 |
Pre. Close: |
22.02 |
|
High:
|
21.8 |
Low:
|
21.6701 |
|
Volume:
|
857 |
Market Cap:
|
282(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 10:48:54 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 31.75 One year: 36.55 |
| Support: |
Support1: 20.54 Support2: 17.08 |
| Resistance: |
Resistance1: 27.18 Resistance2: 31.29 |
| Pivot: |
23.89  |
| Moving Average: |
MA(5): 22.55 MA(20): 24.57
MA(100): 27.14 MA(250): 30.07 |
| MACD: |
MACD(12,26): -1.2 Signal(9): -0.9 |
| Stochastic oscillator: |
%K(14,3): 16.3  %D(3): 15.3 |
| RSI: |
RSI(14): 33.8 |
| 52-week: |
High: 48.29 Low: 20.54 |
| Average Vol(K): |
3-Month: 1 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RGC ] has closed above bottom band by 7.5%. Bollinger Bands are 41.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
22.98 - 23.09 |
23.09 - 23.2 |
|
Low:
|
20.24 - 20.37 |
20.37 - 20.49 |
|
Close:
|
20.3 - 20.51 |
20.51 - 20.71 |
|
Company Description |
|
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. |
Headline News |
Sun, 28 May 2023
CEO Yat-Gai Au, Regencell Bioscience Holdings Limited's (NASDAQ:RGC) largest shareholder sees value of holdings go down 10% after recent drop - Simply Wall St
Mon, 03 Apr 2023
Anyone, Anywhere, You Can Make A Difference! - ValueWalk
Wed, 16 Nov 2022
Regencell Bioscience Holdings Limited's (NASDAQ:RGC) CEO Yat-Gai Au is the most upbeat insider, and their holdings increased by 15% last week - Simply Wall St
Tue, 15 Nov 2022
How Can Healthcare And Alternative Medicine Safely Adopt Artificial ... - Entrepreneur
Mon, 12 Sep 2022
Regencell Bioscience's Standardized Formulae Are Shown to ... - Business Wire
Fri, 01 Jul 2022
Game-Stop Or Game-On? RGC Has It All And Twice More - ValueWalk
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
13 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
88.7 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
4 (K) |
|
Shares Short P.Month
|
4 (K) |
Stock Financials |
|
EPS
|
-0.59 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-51.9 |
|
Return on Equity (ttm)
|
-116.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.58 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-5 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-36.73 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
16.54 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-53.5 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
